HIGHLIGHTS
- who: Xiuying Zhang from the Centred log-ratioBGI-Shenzhen, Shenzhen, China Biology, University of Copenhagen, Copenhagen, Denmark have published the paper: Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial, in the Journal: (JOURNAL)
- what: The authors aimed to assess the impacts of acarbose and vildagliptin on human gut microbiota and the relationships between pre-treatment gut microbiota and therapeutic responses.
- how: To narrow the knowledge gap the authors conducted the VISAT2D (Effect . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.